comparemela.com

Latest Breaking News On - கண் சிமிட்டும் அறிவியல் - Page 1 : comparemela.com

Global COVID-19 At-Home Testing Trends and Market Report 2021: Sample Self Collection Kits, Nasal Swabs Maintain Market Dominance, Saliva Sampling Gains Popularity, Alternative Sampling Innovations

Share this article Share this article ResearchAndMarkets.com s offering. This first edition report At-Home Testing: COVID-19 Trends and Future Potential provides an overview of trends and developments in the home testing industry for the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This report covers trends that have occurred since the pandemic was declared in 2020 to the recent present - March 31, 2021. For the purpose of this report, the analyst concludes that the accepted definition of a home or self-test is one whereby the individual takes the sample, performs the test and then interprets the test result either alone or with the aid of an online consultation service. As of the time of publication in Spring 2021, the major market for COVID-19 self-tests is the United States, therefore the discussion presented in the report focuses on that geography.

ZoomInfo Technologies Inc (ZI) Q4 2020 Earnings Call Transcript

ZoomInfo Technologies Inc. (ZI) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. ZoomInfo Technologies Inc. (NASDAQ: ZI) Q4 2020 Earnings Call Ladies and gentlemen, thank you for standing by, and welcome to the ZoomInfo fourth-quarter and full-year 2020 financial results conference call. [Operator instructions] Please be advised that today s conference may be recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Jerry Sisitsky. Please go ahead, sir. Jerry Sisitsky Investor Relations Great. Thanks, Josh. I appreciate it. Welcome to ZoomInfo s financial results conference call, highlighting our results for the fourth-quarter and the full-year 2020.

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

(Pixabay)                  Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week. Another GSK vaccine exec jumps ship for biotech CEO role GlaxoSmithKline Amir Reichman is stepping down. Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.